Post-marketing surveillance is the continued monitoring of a medicine's safety once it is in widespread use. Clinical trials before approval involve limited numbers of people for limited periods, so rare effects often surface only afterwards.
Reports gathered through programmes such as MedWatch can lead to labeling updates, safety communications, or in rare cases withdrawal.